Sugatrol

• Type 2 Diabetes Mellitus: Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, especially when diet alone is insufficient.
• Postprandial Hyperglycemia: Specifically reduces postprandial blood glucose spikes.
• Off-label Uses: Occasionally used in combination with other antidiabetic agents (e.g., metformin, sulfonylureas) to enhance glycemic control.
• Not indicated for type 1 diabetes or diabetic ketoacidosis.

• Initial dose: 25 mg orally three times daily with the first bite of each main meal.
• Titration: Dose may be increased every 4–8 weeks based on tolerance and efficacy. Common maintenance dose is 50–100 mg three times daily.
• Maximum dose: Up to 100 mg three times daily for patients weighing less than 60 kg; up to 100 mg or more three times daily for those weighing over 60 kg, not exceeding 300 mg/day.
• Pediatric use: Safety and efficacy not established in children under 18 years.
• Elderly: No specific dosage adjustment needed, but monitor for renal function.
• Renal impairment: Use cautiously in mild to moderate renal impairment; contraindicated in severe renal impairment (eGFR <25 mL/min/1.73 m²).
• Hepatic impairment: Use with caution; no formal dose recommendations available.
• Administration: Must be taken with the first bite of each meal for optimal effectiveness.

Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate digestion by competitively inhibiting enzymes such as pancreatic alpha-amylase and intestinal brush border alpha-glucosidases. This slows the breakdown of complex carbohydrates into glucose, resulting in a reduction of postprandial hyperglycemia by blunting the rise of blood glucose after meals.

• Absorption: Minimal systemic absorption (<2%); acts locally in the gastrointestinal tract.
• Distribution: Due to negligible absorption, systemic distribution is minimal.
• Metabolism: Metabolized primarily by intestinal bacteria and digestive enzymes.
• Excretion: Eliminated mainly via feces as inactive metabolites; a small fraction excreted unchanged in urine.
• Half-life: Not clinically relevant because of low systemic exposure.

• Pregnancy: Classified as FDA Pregnancy Category B. Animal studies show no fetal harm, but adequate human studies are lacking. Use only if clearly needed.
• Lactation: Unknown if excreted in human milk; caution is advised during breastfeeding due to lack of data.
• Note: Benefits should outweigh potential risks when prescribing to pregnant or breastfeeding women.

• Primary Class: Antidiabetic agent.
• Subclass: Alpha-glucosidase inhibitor.

• Hypersensitivity to acarbose or any formulation component.
• Diabetic ketoacidosis.
• Cirrhosis.
• Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
• Colonic ulceration or partial intestinal obstruction.
• Conditions predisposing to intestinal obstruction.
• Severe renal impairment (eGFR <25 mL/min/1.73 m²).

• Hypoglycemia risk: When combined with insulin or sulfonylureas, hypoglycemia risk increases. Treat hypoglycemia with glucose (dextrose), not sucrose, as acarbose inhibits sucrose digestion.
• Gastrointestinal effects: Flatulence, diarrhea, and abdominal discomfort are common and usually transient.
• Hepatic effects: Rare cases of elevated liver enzymes have been reported; liver function monitoring recommended if higher doses are used.
• Renal impairment: Use cautiously in mild to moderate impairment.
• Patients with gastrointestinal diseases: Use with caution; monitor for signs of bowel obstruction.
• Early recognition of severe abdominal symptoms is important to rule out serious complications.

• Common: Flatulence, diarrhea, abdominal pain, and bloating. These effects are dose-dependent and usually decrease over time.
• Serious/Rare: Elevated liver enzymes, hypersensitivity reactions (rash, angioedema), and intestinal obstruction in predisposed individuals.
• Side effects typically occur early in treatment.

• Hypoglycemic agents: Increases risk of hypoglycemia with insulin or sulfonylureas.
• Digestive enzyme inhibitors: Potential interactions affecting carbohydrate digestion.
• Food: Must be taken with food for effectiveness.
• Alcohol: No significant interaction, but alcohol may worsen hypoglycemia.
• Metabolism: No significant CYP450 involvement due to minimal systemic absorption.

• Current diabetes guidelines (ADA, EASD) recommend acarbose as a possible adjunct for postprandial glucose control, especially in patients with mild to moderate hyperglycemia.
• No recent major regulatory changes.
• Ongoing monitoring of gastrointestinal tolerability emphasized in recent clinical guidance.

• Store at 20°C to 25°C (68°F to 77°F).
• Protect from moisture and light.
• Keep in original container tightly closed.
• Do not freeze.
• No special refrigeration or reconstitution required.
• Tablets should be swallowed whole; do not crush or chew.